You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: February 28, 2024

Fostemsavir tromethamine - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for fostemsavir tromethamine and what is the scope of patent protection?

Fostemsavir tromethamine is the generic ingredient in one branded drug marketed by Viiv Hlthcare and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Fostemsavir tromethamine has thirty-nine patent family members in thirty countries.

One supplier is listed for this compound.

Summary for fostemsavir tromethamine
International Patents:39
US Patents:3
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 35
Patent Applications: 113
What excipients (inactive ingredients) are in fostemsavir tromethamine?fostemsavir tromethamine excipients list
DailyMed Link:fostemsavir tromethamine at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for fostemsavir tromethamine
Generic Entry Date for fostemsavir tromethamine*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET, EXTENDED RELEASE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for fostemsavir tromethamine

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Viiv Hlthcare RUKOBIA fostemsavir tromethamine TABLET, EXTENDED RELEASE;ORAL 212950-001 Jul 2, 2020 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Viiv Hlthcare RUKOBIA fostemsavir tromethamine TABLET, EXTENDED RELEASE;ORAL 212950-001 Jul 2, 2020 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Viiv Hlthcare RUKOBIA fostemsavir tromethamine TABLET, EXTENDED RELEASE;ORAL 212950-001 Jul 2, 2020 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Viiv Hlthcare RUKOBIA fostemsavir tromethamine TABLET, EXTENDED RELEASE;ORAL 212950-001 Jul 2, 2020 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for fostemsavir tromethamine

Country Patent Number Title Estimated Expiration
Ukraine 88297 ПИПЕРАЗИНОВЫЕ ПРОЛЕКАРСТВА И ЗАМЕЩЕННЫЕ ПИПЕРИДИНОВЫЕ АНТИВИРУСНЫЕ СРЕДСТВА;ПІПЕРАЗИНОВІ ПРОЛІКИ І ЗАМІЩЕНІ ПІПЕРИДИНОВІ АНТИВІРУСНІ ЗАСОБИ (PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS) ⤷  Try a Trial
China 1953985 Prodrugs of piperazine and substituted piperidine antiviral agents ⤷  Try a Trial
Brazil PI0508876 pró medicamentos de agentes antivirais de piperazina e piperidina substituìda ⤷  Try a Trial
Germany 602005004517 ⤷  Try a Trial
Israel 211961 פרודראגים של תרכובות אנטיויראליות של פיפרזין ופיפרידין מותמר (Prodrugs of piperazine and substituted piperidine antiviral agents) ⤷  Try a Trial
New Zealand 585294 Prodrugs of piperazine and substituted piperidine antiviral agents ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.